Literature DB >> 33226187

Catheter directed embolectomy of right atrial clot in transit-A case series.

Isha Verma1,2, Eric Y Chang1,2, Gautam Kumar3,2,4, Rajesh Sachdeva1,3,2.   

Abstract

In the previous literature, the prevalence of right atrial (RA) clot-in-transit associated with pulmonary embolism is around 4-18% with an associated mortality of 80-100% in untreated cases. Surgical thrombo-embolectomy has been the mainstay of treatment for stable patients but the data for percutaneous thrombo-embolectomy is lacking in the literature. We present a series of three cases of right atrium clot-in-transit treated with catheter-based therapies with Inari FlowTriever® (Inari Medical, Irvine, CA). Our three patients had different clinical profiles and presentations of right atrial clot-in-transit. All of the subjects had contraindications to surgical thrombo-embolectomy and thrombolytic therapy. Catheter based embolectomy using Inari FlowTriever® was successfully performed in all the patients. As the data on this intervention is sparse, our case series highlights successful catheter based thrombo-embolectomies in high-risk individuals with right atrial clot in-transit with or without pulmonary embolism.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  Inari FlowTriever; catheter directed embolectomy; embolectomy; right atrial clot in transit

Year:  2020        PMID: 33226187     DOI: 10.1002/ccd.29391

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  2 in total

1.  Clot In Transit in a Patient with Protein S Deficiency.

Authors:  Simon Kashfi; Mohamed Farhan Nasser; Aron Soleiman; Sapna Sharma; Venkata Sandeep Koripalli; Shorabh Sharma
Journal:  Eur J Case Rep Intern Med       Date:  2022-05-05

2.  Percutaneous Aspiration of Vegetation in Tricuspid Valve Infective Endocarditis: A Possible Novel Treatment Option.

Authors:  Abdelkader Almanfi; Ibrahim Nabous
Journal:  JACC Case Rep       Date:  2022-09-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.